Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alligator Bioscience AB ( (SE:ATORX) ) has issued an announcement.
Alligator Bioscience AB has secured 85% of its warrant programme TO 12, with significant subscription and guarantee undertakings from key stakeholders, amounting to approximately SEK 61.6 million. This financial maneuver, along with the renegotiation of an outstanding loan, is aimed at reducing company risk and facilitating the advancement of mitazalimab towards market entry, as the company intensifies discussions with potential strategic partners.
More about Alligator Bioscience AB
Alligator Bioscience AB is a biotechnology company focused on developing innovative immuno-oncology therapies. The company is engaged in advancing its lead product candidate, mitazalimab, through strategic partnerships and regulatory alignments.
Average Trading Volume: 191,019
Current Market Cap: SEK66.54M
Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.